astrazeneca_building_white

AstraZeneca hold internal talks for Medivation takeover – reports

pharmafile | April 18, 2016 | News story | Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover 

AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug company, Medivation (NASDAQ: MDVN).

According to the Sunday Times, the company has yet to make a formal offer for the San-Francisco-based Medivation, which boasts a market cap of $8.38 billion. The firm bases much of its focus in oncology treatments.

AstraZeneca are said to be close to making an offer. This news comes a week after Bloomberg reported that Medivation had rejected an offer from Sanofi (EPA: SAN). Reports also suggest that Medivation had employed the services of Wall Street bank JP Morgan to help fend off unwanted takeovers. Shares in the company have risen as high as 10% in the past week.

Advertisement

Mergers (and failed mergers) are the topic du jour in the pharmaceutical industry this month after the failed Pfizer/Allergan inversion made headlines.

Sean Murray

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

The Gateway to Local Adoption Series

Latest content